PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Videos|September 18, 2026
Introducing the "PharmTech AI Pulse Check" Expert Video Series
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Advertisement
Advertisement
In the debut episode of PharmTech's new biweekly video series, “PharmTech AI Pulse Check,” host Chris Cole, associate editorial director, PharmTech, sits down with three expert co-hosts—Richard Jaenisch, Open Biopharma Research and Training Institute, Florin Muraru, independent regulatory affairs advisor, and Gourav Pandey, R&D quality lead, Takeda—to unpack the AI developments and questions that matter most to people building, manufacturing, and delivering therapies for patients.
Related to this article
API-gated journals may skew pharma regulatory research as AI agents favor accessible sources, raising citation integrity and pharmacovigilance risks.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
Advertisement
Advertisement